Phase 2 study for people with Prostate Cancer

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor AstraZeneca
Registry number NCT07529717
Started 18 May 2026 Today 16 October 2026 Estimated completion 17 November 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Darlinghurst NSW Recruiting
Research Site Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years to 100 Years
Sex Male participants only
Healthy volunteers Not accepted
Enrolment target 42

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Histologically confirmed diagnosis of adenocarcinoma of the prostate or neuroendocrine differentiated prostate cancer

* Surgically or medically castrated with serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L)

* PSA value at screening should be ≥ 1ng/mL

* Evidence of disease progression within 6 months prior to screening

* Part A Participants should have received at least 2 prior approved systemic therapies for prostate cancer with at least one androgen receptor pathway inhibitor and at least one taxane regimen if amenable

* Part B Participants should have received an androgen receptor pathway inhibitor for metastatic hormone sensitive prostate cancer or metastatic castration resistant prostate cancer (mCRPC). No prior taxane treatment for mCRPC is allowed for Module 1 and 2 Part B patients

* Adequate organ function

* Body weight ≥ 35 kg

Exclusion Criteria:

* Any clinically relevant cardiac abnormalities such as QT prolongation or uncontrolled cardiac arrythmias

* All prior treatment-related adverse events must have resolved to Grade ≤ 2

* History of Grade ≥ 3 cytokine release syndrome or Grade ≥ 2 immune effector cell-associated neurotoxicity syndrome with prior therapy

* Active or prior documented autoimmune or inflammatory disorders within the past 3 years

* Prior exposure to any STEAP2 targeted agents or TCEs for prostate cancer

Dates on the record

Started 18 May 2026
Estimated completion 17 November 2027
Registry last updated 9 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 9 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.